version of the Guidelines, which is freely available via the ESC and EAS websites and
hosted on their journals' websites (EHJ and Atherosclerosis Journal). The National Cardiac …

Objective To assess the associations between statins and adverse events in primary
prevention of cardiovascular disease and to examine how the associations vary by type and …

In Japan, a super-aged society, deaths from atherosclerotic cardiovascular disease
(ASCVD), especially cardiac diseases including coronary artery disease (CAD) such as …

Tumor-infiltrating T cells often lose their effector function; however, the mechanisms are
incompletely understood. We report that cholesterol in the tumor microenvironment induces …

Every 5 years, the JAS publishes guidelines for the treatment of dyslipidemia and
atherosclerosis. To date, this society has released four such guidelines. Since 2007, the JAS …

Abstract Treatment with statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A
reductase, has proven beneficial preventive effects on cardiovascular events. However …

Background and aims Patients with hyperlipidemia who are unable to tolerate optimal statin
therapy are at increased cardiovascular risk due to ongoing elevations in low-density …

Since the publication of the guidelines for the assessment and management of non alcoholic
fatty liver disease (NAFLD) by the Asia–Pacific Working Party on NAFLD in 2007, 1 our …

Coenzyme Q (CoQ) is an essential component of the mitochondrial electron transport chain
and an antioxidant in plasma membranes and lipoproteins. It is endogenously produced in …

Statin-associated muscle symptoms (SAMS) are one of the principal reasons for statin non-
adherence and/or discontinuation, contributing to adverse cardiovascular outcomes. This …